UAE's Crescent co-leads surgery robot startup XCath's $30m round

XCath, a medical device startup with campuses in Houston and Pangyo, secured US$30 million in a series C round, brings total capital raised to US$92 million since its 2017 founding.

The funding will support development and future commercialisation of its endovascular surgical robot, as well as a planned clinical telerobotic mechanical thrombectomy.

The round was co-led by Crescent Enterprises and Dr Fred Moll, who chairs XCath’s board.

XCath said surgeons used its Iris robotic system in November 2025 at The Panama Clinic to treat complex brain aneurysms, which the company described as the second intracranial neurovascular intervention performed by a surgical robot.

XCath added that Iris is the only endovascular robotic system in development to achieve intracranial navigation or neurointerventional treatment.

🧠 Food for thought

Implications, context, and why it matters.

The race to solve a healthcare bottleneck is already underway

XCath is one of several teams working on telerobotic mechanical thrombectomy (a procedure that removes a blood clot from a blocked brain artery during a stroke) 1.
Competitor Sentante completed a remote thrombectomy by running a transatlantic procedure between the U.S. and Scotland on a perfused non-living subject (a human cadaver model), with a stated lag of 120 milliseconds 1.
XCath ran a separate test between Abu Dhabi and South Korea on a silicone model, with latency measured at 153-170 milliseconds 2.
Demand for remote options ties back to too few neurointerventional specialists (doctors trained to treat blood-vessel problems in the brain using minimally invasive, catheter-based techniques), with an estimated 10,000 more needed worldwide 3.
This staffing crunch widens the care gap. Analyses referenced by SVIN’s Endovascular Stroke Standards Committee (a standards-setting group within the Society of Vascular and Interventional Neurology) found that, at the time, fewer than 10% of U.S. large-vessel occlusion (LVO) acute ischemic stroke patients might qualify for mechanical thrombectomy 4.

Telerobotics could reshape the economics of specialized stroke care

Telerobotics could make advanced stroke treatment more reachable for more hospitals.
Today, comprehensive stroke center buildouts can demand large spending, including biplane angiography systems (X-ray imaging setups that capture two views at once to guide catheter procedures) that typically exceed $2-3 million per installation 5.
XCath says its system can work with standard monoplane imaging equipment (a single-view angiography setup), which could trim some imaging costs. The company has not said this removes the need for other stroke-center infrastructure.
The approach supports a hub-and-spoke setup. Experts at a central “hub” hospital can perform procedures remotely at smaller, robot-equipped “spoke” sites.
AI-triage software could add speed by spotting large-vessel occlusions with ≥90% accuracy, which can help route patients to thrombectomy-capable hubs faster 3.

🔗 Source: XCath